Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Semo, D; Obergassel, J; Dorenkamp, M; Hemling, P; Strutz, J; Hiden, U; Muller, N; Muller, UA; Zulfikar, SA; Godfrey, R; Waltenberger, J.
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
J CLIN MED. 2023; 12(4): 1356
Doi: 10.3390/jcm12041356
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hiden Ursula
- Strutz Jasmin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG####
- Find related publications in this database (Keywords)
- diabetes mellitus
- empagliflozin
- SGLT-2
- monocytes
- endothelial cells
- vascular dysfunction
- chemotaxis
- reactive oxygen species (ROS)
- glucose transport
- VEGFR-2
- VEGFR-1